This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics, Inc.'s Chief Scientific Officer, James Woodruff Lillie, reported a sale of 11,513 shares on October 15, 2026, at a weighted average price of $8.08 per share; the transactions ranged from $7.755 to $8.3732 per share. The shares were required to be sold to cover statutory tax withholding on vesting restricted stock units under the issuer's equity-plan election, and the sale was not discretionary. No Rule 10b5-1 plan is reported. Direct holdings after the transaction were 198,597 shares.
MapLight Therapeutics, Inc. (MPLT) General Counsel Kristopher Hanson reported the sale of 9,020 shares of Voting Common Stock on October 15, 2026, at a weighted average price of $8.0800 per share. The shares were sold to fund statutory tax withholding obligations tied to restricted stock unit vesting; the issuer's equity-plan election required the sell-to-cover transaction, which the footnote says was not discretionary. Hanson held 128,024 shares directly after the sale. No Rule 10b5-1 plan is reported.
MapLight Therapeutics, Inc. (MPLT) Chief Medical Officer Erin Pennock Foff reported a sale of 15,355 voting common shares on October 15, 2026, at a weighted average price of $8.08 per share. The sale covered minimum statutory tax withholding obligations tied to restricted stock unit vesting under the issuer’s equity-plan election and was not discretionary. She held 296,906 shares directly after the transaction. Per-share sale prices ranged from $7.755 to $8.3732.
MapLight Therapeutics, Inc. reported that Chief Executive Officer and director Christopher A. Kroeger had 73,691 shares of voting common stock sold on October 15, 2026, at a weighted average price of $8.08 per share. The sale was mandated by the issuer’s election under its equity incentive plans to fund statutory tax withholding upon restricted stock unit vesting, rather than being discretionary. After the transaction, Kroeger directly held 1,195,909 shares; C&M Kroeger Nominee Trust held 101,190 shares. Kroeger is a co-trustee with his spouse and has voting and dispositive power over the trust shares.
MapLight Therapeutics, Inc. officer Kris Hanson filed notice of a proposed sale of 9,020 common shares through Jefferies LLC, with an approximate sale date of October 15, 2026 and an aggregate market value of $70,446.20. The shares are to be sold solely to satisfy tax-withholding obligations in connection with restricted stock unit vesting.
MapLight Therapeutics, Inc. officer Jonathan Gillis reported a proposed sale of 10,167 common shares, with an aggregate market value of $79,404.27 and an approximate sale date of October 15, 2026. The shares are to be sold solely to satisfy tax-withholding obligations connected with restricted stock unit vesting. The notice lists Jefferies LLC as broker and Nasdaq as the exchange.
Erin Pennock Foff, an officer of MapLight Therapeutics, Inc. (MPLT), gave notice of a proposed sale of 15,355 common shares, listed at an aggregate market value of $119,922.50. October 15, 2026, is listed as the approximate sale date, with Jefferies LLC as broker and Nasdaq as the exchange. The stated purpose is solely to satisfy tax-withholding obligations in connection with restricted stock unit vesting.
MapLight Therapeutics, Inc. officer Christopher A. Kroeger reported an intended sale of 73,691 common shares for an aggregate market value of $575,526.71, with an approximate sale date of October 15, 2026. The notice also lists prior sales by Christopher Kroeger of 61,778 shares on July 15, 69,082 shares on July 16 and 16,779 shares on July 17, 2026.
MapLight Therapeutics, Inc. officer Lillie James Woodruff plans to sell 11,513 common shares, with an aggregate market value of $89,916.53 and an approximate sale date of October 15, 2026. The notice states the shares are to be sold solely to satisfy tax-withholding obligations connected with RSU vesting.
MapLight Therapeutics, Inc. (MPLT) director Robert Malenka reported a proposed sale of 14,809 common shares, with an approximate sale date of October 15, 2026. The reported aggregate market value is $115,658.29. The securities are identified as restricted stock units acquired from the issuer on October 1, 2026; Morgan Stanley Smith Barney LLC is listed in the broker information.